<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03598634</url>
  </required_header>
  <id_info>
    <org_study_id>0001-05-2018</org_study_id>
    <nct_id>NCT03598634</nct_id>
  </id_info>
  <brief_title>Epi Off Versus Epi on Corneal Collagen Cross-linking in Keratoconus Patients</brief_title>
  <official_title>Epi Off Versus Epi on Corneal Collagen Cross-linking in Keratoconus Patients: a Comparative Study Throught 2 Years Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Molise</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Molise</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate two different techniques of cross linking: standard epithelium off (CXL epi off)
      versus trans-epithelial (CXL epi on) cross linking in patient with progressive keratoconus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to evaluate two different techniques of cross linking: standard
      epithelium off (CXL epi off) versus trans-epithelial (CXL epi on) cross linking in patient
      with progressive keratoconus.

      Forty eyes from 32 patients with progressive keratoconus were prospectively enrolled from
      June 2014 to June 2015 in this non-blinded, randomized comparative study. Twenty eyes were
      treated by CXL epi off and 20 by CLX epi on, randomly assigned and followed for 2 years. All
      patients underwent a complete ophthalmologic testing that included uncorrected and best
      corrected visual acuity, central and peripheral corneal thickness, corneal astigmatism,
      simulated maximum, minimum, and average keratometry, corneal confocal microscopy, Schirmer I
      and break-up time (BUT) tests, and the Ocular Surface Disease Index. Intra-and postoperative
      complications were recorded. The solution used for CXL epi off comprised riboflavin 0.1% and
      dextran 20.0% (Ricrolin), whereas the solution for CXL epi on (Ricrolin, TE) comprised
      riboflavin 0.1%, dextran 15.0%, trometamol (Tris), and ethylene-diamine-tetra-acetic acid.
      Ultraviolet-A treatment was performed with UV-X System at 3 mW/cm2.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2014</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">June 30, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best-corrected visual acuity after treatment</measure>
    <time_frame>up to 48 months from the recruitment</time_frame>
    <description>Scale name: Early treatment diabetic retinopathy study (ETDRS) charts.
Scale range 0-1.
highest value of the range (corresponding to 20/20): 0
lowest value of the range (corresponding to 20/200): 1</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Keratoconus</condition>
  <arm_group>
    <arm_group_label>Epi-on cross-linking</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Drug: Riboflavin 0.15 in 20% dextran solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epi-off cross-linking</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intervention: Drug: Riboflavin 0.15 in 15% dextran solution supplemented with Tris-hydroxymethylaminomethane and sodium ethylenediaminetetraacetic acid</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>administration of riboflavin for epi-off cross-linking</intervention_name>
    <description>riboflavin 0.1% in 20% dextran solution</description>
    <arm_group_label>Epi-off cross-linking</arm_group_label>
    <arm_group_label>Epi-on cross-linking</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>administration of riboflavin for epi-on cross-linking</intervention_name>
    <description>riboflavin 0.1% in 15% dextran solution supplemented with tris-hydroxymethylaminomethane and sodium ethylenediminetetraacetic acid</description>
    <arm_group_label>Epi-off cross-linking</arm_group_label>
    <arm_group_label>Epi-on cross-linking</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with evolving keratoconus

          -  aged between 18 and 40 years

          -  no evidence of corneal scarring

        Exclusion Criteria:

          -  patients with central and paracentral corneal opacities

          -  Vogt's striae

          -  previous intraocular surgery

          -  history of herpetic keratitis

          -  history of severe dry eye

          -  concomitant autoimmune diseases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 12, 2018</study_first_submitted>
  <study_first_submitted_qc>July 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>July 14, 2018</last_update_submitted>
  <last_update_submitted_qc>July 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Molise</investigator_affiliation>
    <investigator_full_name>Ciro Costagliola</investigator_full_name>
    <investigator_title>Full Professor in Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>cross-linking</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riboflavin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Data will be made available once the studies results will be published</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

